MoonLake Immunotherapeutics (MLTX)
Develops new antibody drugs to treat inflammatory skin and joint diseases like psoriasis and arthritis
$19.02-0.04%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-64.1%
The outlook
MLTX is trading near the lower end of its 52-week range, sitting above both its 50- and 200-day moving averages. Analyst consensus leans bullish with an average price target around 47% above the current level. The overall sentiment reflects optimism despite the stock's position in the lower half of its yearly range.
What’s behind the score
Analyst consensusBuy — 1.9 avg of 13 analysts
Price trendAbove its 50- & 200-day averages
52-week range23% of the way from its 52-week low to high
Price targetAvg target +47% vs current price
Analyst price target
~12-month · 13 analysts$28.00average target+47.2% vs now
Now $19.02
Low $6.00High $46.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.62B
52-wk high
$62.75
52-wk low
$5.95
50-day avg
$18.96
200-day avg
$15.99
Trailing P/E
—